


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. 53047/31628	
In Re Application Of: Dugan et al.				
Serial No. 10/083,283	 Filing Date February 23, 2002	Examiner N/A	Group Art Unit 1646	
Title: Carboxyfullerenes and Methods of Use Thereof				
			RECEIVED MAY 28 2002 TECH CENTER 1600/2900	
Address to: Assistant Commissioner for Patents Washington, D.C. 20231				
37 CFR 1.97(b)				
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.				
37 CFR 1.97(c)				
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:				
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);				
OR				
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).				

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. 53047/31628	
In Re Application: Dugan et al.				
Serial No. 10/083,283	Filing Date February 23, 2002	Examiner N/A	Group Art Unit 1646	
Title: Carboxyfullerenes and Methods of Use Thereof				

RECEIVED
 MAY 28 2002
 TECH CENTER 1600/2900

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

☐ A check in the amount of _____ is attached.

☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 20-0823 as described below. A duplicate copy of this sheet is enclosed.

☐ Charge the amount of _____

☒ Credit any overpayment.

☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. _____) on _____ (Date)

 Signature

 Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by Express Mail


I certify that this document and fee is being deposited on May 21, 2002 with the U.S. Postal Service as Express Mail under 37 C.F.R. 1.10 and addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

ExpressMail
No.: EL474165422US

 Signature of Person Mailing Correspondence

Paul A. Lesko
 Typed or Printed Name of Person Mailing Certificate


*This certificate may only be used if paying by deposit account.


 Signature

Paul A. Lesko, Reg. No. 45,364
 Thompson Coburn LLP
 One US Bank Plaza
 St. Louis, Missouri 63101-9928
 314-552-6443
 314-552-7443 FAX

Dated: May 21, 2002

Customer No: 021888



Sheet 1 of 2


Group Art Unit
1646

TECH CENTER 1600/2900

YES	NO
-----	----

DATE CONSIDERED

1901789



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Sheet 2 of 2

(Use several sheets if necessary)

Patent Number
10/083,283

Applicant
Dugan et al.

Filing Date
February 23, 2002

Group Art Unit
1646

[illegible][illegible]

		Donald K. Ingram, et al., "Chronic Treatment Of Aged Mice With L-Deprenyl Produces Marked Striatal MAO-B Inhibition But No Beneficial Effects on Survival, Motor Performance, or Nigral Lipofuscin Accumulation"; <i>Neurobiology of Aging</i> , Vol. 14; (1993) 431-440.
		R.G. Jordens et al., "Prolongation of Life in an Experimental Model of Aging in <i>Drosophila Melanogaster</i> " <i>Neurochemical Research</i> , Vol. 24, No. 2; (1999) 227-233.
		W. Birkmayer, et al., "Increased Life Expectancy Resulting from Addition of L-Deprenyl to Madopar Treatment in Parkinson's Disease: A Longterm Study"; <i>Journal of Neural Transmission</i> , 64; (1985) 113-127.
		Y. Ben-Shlomo, et al., "Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease; further results of randomized trial and confidential inquiry"; <i>BMJ</i> Vol. 316 (April 18, 1998); 1191-1196.
		P.J. Krusic, et al., "Radical Reactions of C60"; <i>Science</i> Vol. 254; (November 22, 1991) 1183-1185.
		Laura Dugan et al., "Rapid microplate assay for superoxide scavenging efficiency"; <i>Journal of Neuroscience Methods</i> 97; (2000) 139-144.

DATE CONSIDERED